Aurélie Parzy

515 total citations
15 papers, 99 citations indexed

About

Aurélie Parzy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Aurélie Parzy has authored 15 papers receiving a total of 99 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Aurélie Parzy's work include Pancreatic and Hepatic Oncology Research (4 papers), Colorectal and Anal Carcinomas (4 papers) and Cancer Genomics and Diagnostics (4 papers). Aurélie Parzy is often cited by papers focused on Pancreatic and Hepatic Oncology Research (4 papers), Colorectal and Anal Carcinomas (4 papers) and Cancer Genomics and Diagnostics (4 papers). Aurélie Parzy collaborates with scholars based in France, Luxembourg and United States. Aurélie Parzy's co-authors include Mélanie Dos Santos, Marie‐Pierre Galais, Bénédicte Clarisse, Olivier Rigal, Idlir Licaj, Corinne Delcambre, Isabelle Hardy‐Léger, Jérôme Barrière, Sarah Dauchy and Sabine Noal and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Aurélie Parzy

14 papers receiving 99 citations

Peers

Aurélie Parzy
Nine de Graaf Netherlands
Michael Dong Australia
Benedetta Fabrizzi Italy
Xuming Hu China
Anne J. Stone United States
Rachel Baldwin‐Cleland United Kingdom
Andrea Romboli Italy
Jean Jacques De Bruycker Canada
Anne Miek Koenen Netherlands
Romain Trésorier France
Nine de Graaf Netherlands
Aurélie Parzy
Citations per year, relative to Aurélie Parzy Aurélie Parzy (= 1×) peers Nine de Graaf

Countries citing papers authored by Aurélie Parzy

Since Specialization
Citations

This map shows the geographic impact of Aurélie Parzy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurélie Parzy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurélie Parzy more than expected).

Fields of papers citing papers by Aurélie Parzy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aurélie Parzy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurélie Parzy. The network helps show where Aurélie Parzy may publish in the future.

Co-authorship network of co-authors of Aurélie Parzy

This figure shows the co-authorship network connecting the top 25 collaborators of Aurélie Parzy. A scholar is included among the top collaborators of Aurélie Parzy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurélie Parzy. Aurélie Parzy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Ducreux, Michel, Yves Rinaldi, Frédéric Di Fiore, et al.. (2025). PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma. Journal of Clinical Oncology. 43(20). 2255–2264. 3 indexed citations
2.
Elie, Caroline, Karine Bouhier‐Leporrier, Aurélie Parzy, et al.. (2025). ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer. British Journal of Cancer. 132(9). 814–821.
3.
4.
5.
Santos, Mélanie Dos, Justine Lequesne, Alexandra Leconte, et al.. (2022). Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). BMC Cancer. 22(1). 537–537. 17 indexed citations
6.
Kim, Stéfano, François Ghiringhelli, Christelle de la Fouchardière, et al.. (2022). Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study.. Journal of Clinical Oncology. 40(16_suppl). 3508–3508. 10 indexed citations
7.
8.
Lequesne, Justine, Jean‐Michel Grellard, Aurélie Parzy, et al.. (2021). Interim analysis of a phase II study of simultaneously integrated boost intensity modulated radiation therapy (SIB-IMRT) in combination with 5-FU and mitomycin-C among patients with locally advanced anal canal cancer.. Journal of Clinical Oncology. 39(15_suppl). e15501–e15501. 1 indexed citations
9.
Santos, Mélanie Dos, Isabelle Hardy‐Léger, Olivier Rigal, et al.. (2020). Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3‐arm randomized trial. Cancer. 126(24). 5328–5336. 39 indexed citations
10.
Ollivier, Luc, Mélanie Dos Santos, E. Meyer, et al.. (2019). Implantation of tissue expander prior to irradiation in the era of intensity modulated radiotherapy: impact on the management of patients with pelvic digestive cancers. International Journal of Colorectal Disease. 35(3). 559–564. 1 indexed citations
11.
Santos, Mélanie Dos, Olivier Rigal, Idlir Licaj, et al.. (2019). Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A randomized controlled multicenter trial.. Journal of Clinical Oncology. 37(15_suppl). 11521–11521. 3 indexed citations
12.
Laurent, Lucie, David Sefrioui, Aurélie Parzy, et al.. (2018). CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts. HPB. 21(5). 582–588. 15 indexed citations
13.
Ducreux, Michel, Matthieu Texier, Frédéric Di Fiore, et al.. (2018). PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC). Annals of Oncology. 29. viii266–viii267. 3 indexed citations
14.
15.
Ducoulombier, Agnès, Vincent Hautefeuille, Christophe Desauw, et al.. (2015). 2294 Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma. European Journal of Cancer. 51. S430–S430. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nine de Graaf Breakdown of academic impact, for papers by Michael Dong Breakdown of academic impact, for papers by Benedetta Fabrizzi Breakdown of academic impact, for papers by Xuming Hu Breakdown of academic impact, for papers by Anne J. Stone Breakdown of academic impact, for papers by Rachel Baldwin‐Cleland Breakdown of academic impact, for papers by Andrea Romboli Breakdown of academic impact, for papers by Jean Jacques De Bruycker Breakdown of academic impact, for papers by Anne Miek Koenen Breakdown of academic impact, for papers by Romain Trésorier
Rankless by CCL
2026